Mirum Pharmaceuticals, Inc. (MIRM) Misses Q2 EPS by 5c ; Offers Guidance

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q2 EPS of ($0.52), $0.05 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $77.8 million versus the consensus estimate of $75.2 million.

GUIDANCE:

Mirum Pharmaceuticals, Inc. sees FY2024 revenue of $310-320 million, versus the consensus of $312.7 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Texas Capital Securities Downgrades Arcosa (ACA) to Hold